NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH NeuroBo Pharmaceuticals Receives Safety...
NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity NeuroBo Pharmaceuticals Receives First Site IRB Approval for...
NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO Get Free Report)s stock price was up 1.3% on Thursday . The company traded as high as $4.96 and last traded at $4.83. Approximately 27,776...
NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference PR Newswire CAMBRIDGE, Mass., Feb. 12, 2024...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1...
NeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the...
NeuroBo to Participate in Industry and Investor Conferences in January NeuroBo to Participate in Industry and Investor Conferences in January PR Newswire CAMBRIDGE, Mass., Jan. 2, 2024 CAMBRIDGE...